Taxane/anthracycline combinations: Setting a new standard in breast cancer?

Oncologist

Volumn 6, Issue SUPPL. 3, 2001, Pages 5-12

  Nabholtz, Jean Marc ^a,b   Riva, Alessandro ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant; Anthracycline; Docetaxel; Doxorubicin; Metastatic breast cancer; Taxane

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; HUMANS; TAXOIDS;

EID: 0035036545     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_3-5     Document Type: Conference Paper

References (26)

1. Cancer statistics, 1999
2. Chemotherapy of Breast Cancer
3. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer
4. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
5. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
6. Chemotherapy of breast cancer: Are the taxanes going to change the natural history of breast cancer?
7. Docetaxel overview: A drug that has earned its place in innovative therapy
8. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
9. Docetaxel in combination with doxorubicin: A phase I dose-finding study
10. Phase II study of docetaxel in combination with doxorubicin as 1st line therapy of metastatic breast cancer
11. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer
12. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196
13. Doxorubicin and Taxotere: A pharmacokinetic study of the combination in advanced breast cancer
14. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol
15. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-sequence-finding study
16. Combined doxombicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
17. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
18. Eastern Cooperative Oncology Group study of paclitaxel and doxorubicin in advanced breast cancer
19. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
20. Phase I/II study of 72 hours infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
21. A phase III trial comparing doxombicin and docetaxel (AT) to doxorubicin and cyclophosphamide (AC) as first line therapy for MBC
22. Phase III trial of doxorubicin vs paclitaxel vs doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup Trial
23. Randomized open-label phase III multicenter trial comparing Taxol®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer
24. Doxorubicin (A)/Taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study
25. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC)
26. CAF in metastatic breast cancer: Standard therapy or another effective regimen?